官方新闻稿指出，Breyanzi在边缘区淋巴瘤（MZL）队列中达到了总缓解率（ORR）的主要终点及完全缓解率（CRR）的关键次要终点，结果展现出统计学显著性。同时，Breyanzi表现出持久的疗效和一致的安全性特征，且未观察到新的安全性信号。

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

State Common Entrance Test Cell, Maharashtra has extended the registration window for several exams. Through two official ...

Jim Cramer, the host of Mad Money, recently pointed out a significant gap in the American education system, emphasizing that ...

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

What's next for the Persistent War? Before the big Airborne update, Foxhole is rolling out some quality-of-life improvements.

The MAH CET 2025 registration deadline has been extended for several courses, including MAH-M.Ed, MAH-M.P.Ed, and MAH-LLB 3 ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

If more parking becomes available at a later date, BMS will notify ticket holders that new inventory is available for online ... FAQ: Please click here for additional details. Rendered views are ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Bausch Health Companies Inc.